Physician profile
Ramesh Arora
NPI 1619964095
$3,111.01
in general payments reported to CMS, 2019-2025
13 companies · $80.30 in 2025
The $80.30 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,527 · 2020: $288 · 2021: $619 · 2022: $327 · 2023: $115 · 2024: $155 · 2025: $80.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $350.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,863.89 | 2019-2025 | Aveir, Jot Dx, Merlin@Home |
| Novartis Pharmaceuticals Corporation | $317.12 | 2019-2024 | |
| Gilead Sciences, INC. | $176.92 | 2019 | |
| Amgen INC. | $150.80 | 2019-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $122.34 | 2019-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $112.88 | 2019-2022 | |
| Medtronic Vascular, INC. | $99.19 | 2019 | |
| Pfizer INC. | $97.68 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $65.25 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.04 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $42.46 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $18.44 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramesh Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.